US EditionSERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
CytoSorbents achieved 10% revenue growth to $9.5 million in Q3 2025 and advanced FDA regulatory steps for DrugSorb-ATR with a decision expected mid-2026.
- On Wednesday Nov. 12, 2025, Ace Hardware Corporation reported third quarter revenues of $2.5 billion, up 5.5 percent, in a press release with a conference call.
- The amended credit agreement with Avenue Capital Group, earlier this year, provided $2.5 million in immediate funding and included warrants at $0.70, with proforma cash of $11.6 million on September 30, 2025.
- Earlier this month the company filed a pre-submission meeting request filed November 7, 2025 with the U.S. Food and Drug Administration, expecting a formal De Novo submission in Q1 2026 and a mid-2026 regulatory decision timeline after no safety concerns but additional information requests.
- As part of the plan, CytoSorbents expects to record restructuring charges, including a $900,000 expected restructuring charge, while reducing its workforce by approximately 10% and targeting cash-flow break-even in the first quarter of 2026.
- Recent clinical presentations, including data at European Association for Cardio-Thoracic Surgery , support the planned De Novo filing with the U.S. FDA and Health Canada, including new real-world analyses.
98 Articles
98 Articles
MDA SPACE REPORTS THIRD QUARTER 2025 RESULTS
Q3 2025 HighlightsBacklog of $4.4 billion at quarter-end, provides revenue visibility for 2025 and beyondRevenues of $409.8 million, up 45% YoYAdjusted EBITDA 1 of $82.8 million, up 49% YoY, and adjusted EBITDA margin 1 of 20.2%Adjusted net income 1 of…
Atlas Energy Reports Third Quarter 2025 Financial Results
CALGARY, Alberta, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Atlas Energy Corp. (“Atlas” or the “Company”) (TSXV: ATLE), a TSXV Sandbox issuer, is pleased to announce its unaudited consolidated interim financial statements and related management’s discussion and analysis (“MD&A”) for the…
Aptose Reports Third Quarter 2025 Results
Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose LevelsPatients are Now Being Treated at 160 mg Dose of Tuspetinib
Coverage Details
Bias Distribution
- 54% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
